<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483505</url>
  </required_header>
  <id_info>
    <org_study_id>ROGABREAST</org_study_id>
    <secondary_id>2020-000055-12</secondary_id>
    <nct_id>NCT04483505</nct_id>
  </id_info>
  <brief_title>Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.</brief_title>
  <acronym>ROGABREAST</acronym>
  <official_title>Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion CRIS de Investigación para Vencer el Cáncer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion CRIS de Investigación para Vencer el Cáncer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open, multicenter, prospective phase I dose escalation clinical trial
      followed by an expansion cohort. The aim of this study is to asses the Recommended Phase 2
      Dose (R2PD) and the safety profile, among other efficacy, in FGFR1/2/3 positive, hormone
      receptor-positive breast cancer (HRPBC) patients with metastatic disease after progression to
      the combination of an aromatase inhibitor plus palbociclib, abemaciclib or ribociclib,
      according RECIST 1.1 criteria.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 3, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, prospective, multicenter, single-arm, phase I dose-escalation study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose</measure>
    <time_frame>2 months</time_frame>
    <description>Highest dose at which &lt;1 out of 6 patients experience a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Event</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients with each adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from the date of first dose of study treatment to the date of progression or death (from any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic interactions of fulvestrant and palbociclib over rogaratinib metabolism.</measure>
    <time_frame>16 days</time_frame>
    <description>Plasmatic levels of fulvestrant, palbociclib and rogaratinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic markers levels of FGFR1 Blockade</measure>
    <time_frame>16 days</time_frame>
    <description>Plasma levels of phosphate and FGF23.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients that achieve response according to RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Breast Cancer Metastatic</condition>
  <condition>Hormone Receptor Positive Malignant Neoplasm of Breast</condition>
  <arm_group>
    <arm_group_label>Rogaratinib + palbociclib + fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination, Rogaratinib + palbociclib + fulvestrant</intervention_name>
    <description>Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days.
Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows:
Level 1: Rogaratinib 400 mg PO BID + standard fulvestrant 500 mg every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 3 patients).
Level 2: Rogaratinib 600 mg PO BID + fulvestrant 500 mg IM every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 6 patients).
Treatment will continue until disease progression.</description>
    <arm_group_label>Rogaratinib + palbociclib + fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women ≥18 years-old.

          2. Diagnostic of metastatic or locally advanced non-resectable breast cancer.

          3. Ability to understand and signing of the PIS/ICF for FGFR testing. FGFR testing will
             be performed centrally at CNIO (RNAscope and FISH).

          4. Ability to understand and signing the written PIS/ICF for study treatment eligibility.

          5. Availability of fresh tumor biopsy specimen for FGFR1/3 mRNA expression and FISH
             testing.

          6. Hormone-receptor positivity defined by at least 5% positivity of ER and/or PR (no
             central laboratory testing is required).

          7. Positivity of FGFR1/2/3 by RNA-scope and/or FISH.

          8. Patients must have undergone a previous hormonal treatment line for metastatic
             disease, with anastrozole, letrozole or exemestane, plus a cell cycle inhibitor
             (palbociclib, ribociclib or abemaciclib).

          9. Recovery of toxicities from previous regimens to equal or below tolerable grade II.

         10. HER2-negativity (Herceptest 0+, 1+ or 2+ with negative FISH/CISH/SISH).

         11. ECOG performance status of 0/1.

         12. Life expectancy of &gt;24 weeks.

         13. Adequate bone marrow, liver and renal function as assessed by laboratory requirements:

               1. Absolute neutrophil count (ANC) ≥ 1,500/mm3

               2. Hemoglobin ≥ 10 g/dL (without transfusion or erythropoietin .

               3. Platelet count ≥ 100,000/mm3

               4. Total bilirubin ≤ 1.5 × the upper limit of normal (ULN).

               5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN

               6. Alkaline phosphatase ≤ 2.5 times ULN

               7. Lipase and amylase ≤ 2 × ULN.

               8. Serum albumin ≥ 2.5 g/dl.

               9. Glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m2

         14. INR ≤ 1.5 × ULN and PTT or activated PTT (aPTT) ≤ 1.5 × ULN.

         15. Negative serum pregnancy test in women of childbearing potential.

         16. Women of reproductive potential must agree to use highly effective contraception when
             sexually active.

         17. Evaluable disease according to RECIST 1.1 criteria.

        Exclusion Criteria:

          1. Involvement in the planning and/or conduct the study.

          2. Previous enrollment in the present study.

          3. Previous or concurrent cancer except:

               1. Cervical carcinoma in situ.

               2. Treated basal-cell carcinoma or squamous cell skin cancer.

               3. Any other cancer curatively treated &gt; 3 years before the first study drug
                  administration.

          4. Receipt the last dose of anticancer therapy at least 21 days prior to the first dose
             of study drug.

          5. Acute toxic effects of previous anticancer chemotherapy or immunotherapy have to be
             normalized completely

          6. Anti-cancer therapy is defined as any agent or combination of agents with clinically
             proven anti-tumor activity

          7. Previous treatment with anti-FGFR directed therapies.

          8. Irradiation of single bony lesions with risk of fracture. Zoledronic acid or denosumab
             started prior to trial registration is allowed.

          9. Symptomatic metastatic brain or meningeal tumors.

         10. History or current condition of an uncontrolled cardiovascular disease including any
             of the following conditions:

               1. Congestive heart failure, unstable angina (symptoms of angina at rest) or

               2. New-onset angina

               3. Myocardial infarction (MI).

               4. Unstable cardiac arrhythmias requiring anti-arrhythmic therapy.

               5. Patients with known coronary artery disease, congestive heart failure not meeting
                  the above criteria, must be on a stable medical regimen.

         11. Known human immunodeficiency virus (HIV) infection.

         12. Active hepatitis B virus or hepatitis C infection requiring treatment.

               1. Patients with past HBV infection or resolved HBV infection are eligible if HBV
                  DNA is negative.

               2. Patients positive for hepatitis C virus are eligible only if polymerase chain
                  reaction is negative for HCV RNA.

         13. Any condition that in the opinion of the investigator would interfere with evaluation
             of study treatment or interpretation of patient safety or study results, or inability
             to comply with the study and follow-up procedures.

         14. Previous or concomitant participation in another clinical study with investigational
             medicinal products.

         15. Active tuberculosis.

         16. Clinically active infections.

         17. Treatment with therapeutic oral or i.v. antibiotics.

         18. Patients receiving prophylactic antibiotics are eligible.

         19. Seizure disorder requiring medication.

         20. History of organ allograft.

         21. Evidence or history of bleeding diathesis or coagulopathy.

         22. Any hemorrhage / bleeding event CTCAE v.5.0 ≥ Grade 3.

         23. Serious, non-healing wound, ulcer or bone fracture.

         24. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation.

         25. Any malabsorption condition.

         26. Current diagnosis of any retinal disorders including retinal detachment, retinal
             pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion.

         27. Peripheral sensory neuropathy of CTCAE v.5.0 Grade 2 or higher.

         28. Current evidence of endocrine alteration of calcium phosphate homeostasis.

         29. Concomitant therapies that are known to increase serum phosphate levels.

         30. Any condition that is unstable or could jeopardize the safety of the patient and their
             compliance in the study.

         31. Breast-feeding.

         32. Use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4.

         33. Autologous bone marrow transplant or stem cell rescue.

         34. Major surgery, open biopsy or significant traumatic injury.

         35. Renal failure requiring peritoneal dialysis or hemodialysis.

         36. Systolic/diastolic blood pressure ≤ 100/60 mmHg and concurrent heart rate ≥ 100/min.

         37. Inability to swallow oral tablets.

         38. Close affiliation with the investigational site; e.g. a close relative of the
             investigator or a dependent person.

         39. Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results.

         40. Arterial or venous thrombotic events or embolic events such as cerebrovascular
             accident, deep vein thrombosis or pulmonary embolism.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>In this case gender is important because it is a specific cancer in women.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Ángel Quintela-Fandino</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Nacional de Investigaciones Oncológicas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Manso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramón Colomer i Bosch</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miguel Ángel Quintela-Fandino, MD</last_name>
    <phone>+34917328000</phone>
    <email>mquintela@cnio.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Català d'oncologia - Hospital Duran I Reynals</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Sonia Pernas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sonia Pernas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Miguel Quintela-Fandino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Miguel Ángel Quintela-Fandino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Quirónsalud Madrid</name>
      <address>
        <city>Pozuelo De Alarcón</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Miguel Ángel Quintela-Fandino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Miguel Ángel Quintela-Fandino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Serafín Morales, MD</last_name>
    </contact>
    <investigator>
      <last_name>Serafín Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Noelia Martínez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Noelia Martínez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José Ángel García Saenz, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Ángel García Saenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Luis Manso</last_name>
    </contact>
    <investigator>
      <last_name>Luis Manso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Begoña Bermejo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Begoña Bermejo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

